The addition of monkey NGAL (neutrophil gelatinase-associated lipocalin) further extends our market leading NGAL antibody portfolio, and enables us to bridge the existing gap between pre-clinical drug discovery and clinical trials. We are closing the gap as our nephrotoxicity antibody range now includes antibodies from rat, mouse, pig, dog, monkey and human. As a result, drug discovery projects now have the ability to raise the kidney safety profile of a compound in pre-clinical phases while at the same time having an ability to predict human response to a compound in clinical trials.
About NGAL Monkey antibodies
The NGAL monkey antibodies reacts with NGAL from cynomolgus (Macaca fascicularis) and rhesus (Macaca mulatta) and can be used in a variety of different applications. Monkey NGAL, which by analogy with its homologues in other mammalian species, is released from activated neutrophils in inflammation or infection, from certain epithelial cancers, and more dramatically from renal tubular cells in response to ischemic or nephrotoxic injury.
The monkey or non-human primate (NHP) is an important experimental model for medical research because of its close resemblance to the human physiology, and emphasizes our outstanding focus on renal injury and nephrotoxicity through all stages of drug discovery and clinical research.